ECSP077131A - Regímenes y los juegos de anticonceptivos del antagonista del receptor de progesterona - Google Patents

Regímenes y los juegos de anticonceptivos del antagonista del receptor de progesterona

Info

Publication number
ECSP077131A
ECSP077131A EC2007007131A ECSP077131A ECSP077131A EC SP077131 A ECSP077131 A EC SP077131A EC 2007007131 A EC2007007131 A EC 2007007131A EC SP077131 A ECSP077131 A EC SP077131A EC SP077131 A ECSP077131 A EC SP077131A
Authority
EC
Ecuador
Prior art keywords
contraceptive
regimes
games
progesterone
receiver antagonist
Prior art date
Application number
EC2007007131A
Other languages
English (en)
Inventor
Andrew Fensome
Gary Grubb
Casey Cameron Mccomas
Michael Anthony Marella
Ginger Dale Constantine
Edward George Melenski
Jay Edward Wroble
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077131(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP077131A publication Critical patent/ECSP077131A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método de anticoncepción es provisto, el cual, implica el reparto de 21 a 27 días consecutivos de uno ó más antagonistas del PR en la ausencia de una progestina, estrógeno u otro compuesto esteroidal, seguido por 1 a 7 días sin ningún agente activo. También descrito es un juego farmacéutico útil para facilitar el reparto de este régimen.
EC2007007131A 2004-07-07 2007-01-05 Regímenes y los juegos de anticonceptivos del antagonista del receptor de progesterona ECSP077131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58588304P 2004-07-07 2004-07-07
US67613505P 2005-04-29 2005-04-29

Publications (1)

Publication Number Publication Date
ECSP077131A true ECSP077131A (es) 2007-02-28

Family

ID=35106665

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007131A ECSP077131A (es) 2004-07-07 2007-01-05 Regímenes y los juegos de anticonceptivos del antagonista del receptor de progesterona

Country Status (20)

Country Link
US (1) US20060009509A1 (es)
EP (1) EP1773323A1 (es)
JP (1) JP2008505906A (es)
KR (1) KR20070039912A (es)
AR (1) AR049664A1 (es)
AU (1) AU2005271974A1 (es)
BR (1) BRPI0512993A (es)
CA (1) CA2571198A1 (es)
CR (1) CR8800A (es)
EC (1) ECSP077131A (es)
GT (1) GT200500186A (es)
IL (1) IL180238A0 (es)
MX (1) MXPA06014580A (es)
NO (1) NO20070377L (es)
PA (1) PA8638501A1 (es)
PE (1) PE20060485A1 (es)
RU (1) RU2006144069A (es)
SV (1) SV2006002166A (es)
TW (1) TW200605880A (es)
WO (1) WO2006017075A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
CN104208067A (zh) 2004-07-07 2014-12-17 惠氏公司 周期性黄体酮方案及试剂盒
DE602005026290D1 (de) 2004-07-09 2011-03-24 Population Council Inc Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2010045251A2 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP3106167A1 (en) 2009-04-14 2016-12-21 Laboratoire HRA Pharma Method for on-demand contraception
CA2763960C (en) 2009-06-18 2014-07-08 Pfizer Inc. Bicyclic and tricyclic compounds as kat ii inhibitors
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
AU2010306768B2 (en) 2009-10-14 2016-08-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
MY165117A (en) 2010-02-26 2018-02-28 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
AU2011336214B2 (en) 2010-12-01 2015-08-20 Pfizer Inc. KAT II inhibitors
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP2016510791A (ja) * 2013-03-14 2016-04-11 ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ 排卵の予定を決める方法
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
JP2018522854A (ja) 2015-06-22 2018-08-16 リポカイン インコーポレーテッド １７−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
AR049664A1 (es) 2006-08-23
IL180238A0 (en) 2007-07-04
PA8638501A1 (es) 2006-07-03
CR8800A (es) 2007-08-28
JP2008505906A (ja) 2008-02-28
SV2006002166A (es) 2006-05-09
RU2006144069A (ru) 2008-08-20
GT200500186A (es) 2006-03-02
PE20060485A1 (es) 2006-06-24
BRPI0512993A (pt) 2008-04-22
US20060009509A1 (en) 2006-01-12
NO20070377L (no) 2007-02-07
TW200605880A (en) 2006-02-16
EP1773323A1 (en) 2007-04-18
AU2005271974A1 (en) 2006-02-16
CA2571198A1 (en) 2006-02-16
WO2006017075A1 (en) 2006-02-16
KR20070039912A (ko) 2007-04-13
MXPA06014580A (es) 2007-03-23

Similar Documents

Publication Publication Date Title
ECSP077131A (es) Regímenes y los juegos de anticonceptivos del antagonista del receptor de progesterona
AR049707A1 (es) Regimenes y kits de progestina ciclica
DK1768625T3 (da) Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
NI201000183A (es) Regímenes de dosificación de antiprogestina.
MA26843A1 (fr) NOUVELLES COMPOSITIONS ESTRO-PROGESTATIVES TOPIQUES à EFFET SYSTÉMIQUE
PE20060467A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
HN2008000621A (es) Metodo para la anticopcepcion hormonal preventiva bajo demanda
CY1108562T1 (el) Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
NZ615430A (en) Method for on-demand contraception
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
PE20070208A1 (es) Anticoncepcion oral con trimegestona
JP2010539153A5 (es)
AR065585A1 (es) Antagonistas del receptor de mineralocorticoides para el tratamiento de endometriosis uso
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
AR070302A1 (es) Composicion farmaceutica de un sistema de liberacion vaginal de esteroides
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
AR039228A1 (es) Terapia de reemplazo hormonal
DOP2007000122A (es) Forma farmacologica peroral para anticoncepcion
CO6270329A2 (es) Uso de gestageno en combinacion con un estrogeno y uno o varios excipientes / portadores farmaceuticamente acepptables para la anticoncepcion oral sin lactosa
AR039477A1 (es) Terapia de reemplazo hormonal